- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment of gastric adenocarcinoma: a rapidly evolving landscape
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages 113370
Publisher
Elsevier BV
Online
2023-10-18
DOI
10.1016/j.ejca.2023.113370
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
- (2023) Markus H. Moehler et al. JOURNAL OF CLINICAL ONCOLOGY
- Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis.
- (2023) John V. Reynolds et al. JOURNAL OF CLINICAL ONCOLOGY
- INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
- (2023) Nick Pavlakis et al. JOURNAL OF CLINICAL ONCOLOGY
- VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
- (2023) S.Y. Rha et al. ANNALS OF ONCOLOGY
- Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
- (2023) Thorsten O. Goetze et al. INTERNATIONAL JOURNAL OF CANCER
- Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.
- (2023) Shuqiang Yuan et al. JOURNAL OF CLINICAL ONCOLOGY
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
- (2023) Kohei Shitara et al. LANCET
- O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
- (2023) E. Smyth et al. ANNALS OF ONCOLOGY
- ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.
- (2023) Masanori Terashima et al. JOURNAL OF CLINICAL ONCOLOGY
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
- (2023) Manish A. Shah et al. NATURE MEDICINE
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
- (2022) Yoon-Koo Kang et al. LANCET ONCOLOGY
- Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
- (2022) Howard P Safran et al. LANCET ONCOLOGY
- PD‐L1 immunohistochemistry: Clones, cutoffs, and controversies
- (2022) Ivan Chebib et al. APMIS
- MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
- (2022) Yelena Y Janjigian et al. Future Oncology
- Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
- (2022) Weijie Cao et al. Biomarker Research
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2022) F. Lordick et al. ANNALS OF ONCOLOGY
- Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial
- (2022) Clélia Coutzac et al. DIGESTIVE AND LIVER DISEASE
- Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
- (2022) Joe Yeong et al. Gastric Cancer
- Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
- (2022) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
- (2022) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
- (2022) Ralf-Dieter Hofheinz et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers in gastric cancer
- (2022) C. Röcken JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
- (2022) Zev A Wainberg et al. LANCET ONCOLOGY
- Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer
- (2022) Harry H. Yoon et al. JAMA Oncology
- Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
- (2022) Kensei Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Current developments in gastric cancer: from molecular profiling to treatment strategy
- (2022) Maria Alsina et al. Nature Reviews Gastroenterology & Hepatology
- Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
- (2021) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
- (2021) Tamara Z. Dabbagh et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
- (2021) Josep Tabernero et al. Future Oncology
- Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
- (2021) Ben M. Eyck et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
- (2021) Soomin Ahn et al. MODERN PATHOLOGY
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
- (2021) Harriet R. Ferguson et al. Cells
- LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
- (2021) E. van Cutsem et al. ANNALS OF ONCOLOGY
- LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
- (2021) J. Xu et al. ANNALS OF ONCOLOGY
- 1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
- (2021) M. Moehler et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
- (2021) Jong-Mu Sun et al. LANCET
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
- (2021) Xiaotian Zhang et al. LANCET ONCOLOGY
- TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
- (2021) Alessandra Raimondi et al. Cancers
- Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction
- (2021) Matthieu Faron et al. EUROPEAN JOURNAL OF CANCER
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
- (2021) Yelena Y. Janjigian et al. NATURE
- 18F-Fludeoxyglucose–Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer
- (2021) Emma C. Gertsen et al. JAMA Surgery
- Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
- (2020) Juliette Palle et al. DRUGS
- Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
- (2020) Markus H. Moehler et al. JOURNAL OF CLINICAL ONCOLOGY
- VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
- (2020) Elizabeth Smyth et al. Frontiers in Oncology
- The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.
- (2020) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy
- (2020) Katherine I Zhou et al. CLINICAL CANCER RESEARCH
- Gastric cancer
- (2020) Elizabeth C Smyth et al. LANCET
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Acquired somatic MMR deficiency is a major cause of MSI tumor in patients suspected for “Lynch-like syndrome” including young patients
- (2020) Cedrick Lefol et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort
- (2020) Daniel R. Principe et al. Scientific Reports
- Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
- (2019) Ugur Sahin et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
- (2019) Yung-Jue Bang et al. Future Oncology
- Testing algorithm for identification of patients with TRK fusion cancer
- (2019) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL PATHOLOGY
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
- (2019) Salah-Eddin Al-Batran et al. LANCET
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- Instabilité des microsatellites et cancer
- (2019) Ada Collura et al. M S-MEDECINE SCIENCES
- The 2019 WHO classification of tumours of the digestive system
- (2019) Iris D. Nagtegaal et al. HISTOPATHOLOGY
- Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
- (2019) Filippo Pietrantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
- (2019) Li-Tzong Chen et al. Gastric Cancer
- P-089Gastric cancer in Lynch Syndrome: Are precancerous conditions co- risk factors?
- (2018) M Fornasarig et al. ANNALS OF ONCOLOGY
- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
- (2018) J Adam et al. ANNALS OF ONCOLOGY
- Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)
- (2018) Aziz Zaanan et al. DIGESTIVE AND LIVER DISEASE
- Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
- (2018) Aziz Zaanan et al. DIGESTIVE AND LIVER DISEASE
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- 83POlaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
- (2018) Y-Z Liu et al. ANNALS OF ONCOLOGY
- Immunotherapy in advanced gastric cancer, is it the future?
- (2018) C. Coutzac et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
- (2017) Eirini Pectasides et al. Cancer Discovery
- Gastric adenocarcinoma
- (2017) Jaffer A. Ajani et al. Nature Reviews Disease Primers
- Mismatch Repair Deficiency, Microsatellite Instability, and Survival
- (2017) Elizabeth C. Smyth et al. JAMA Oncology
- PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
- (2017) Lihu Gu et al. PLoS One
- Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant
- (2016) Jun Li et al. AMERICAN JOURNAL OF HUMAN GENETICS
- ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
- (2016) Jens Hoeppner et al. BMC CANCER
- The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015
- (2016) Giovanni De Manzoni et al. Gastric Cancer
- Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
- (2016) Sarah Derks et al. Oncotarget
- TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
- (2015) Trevor Leong et al. BMC CANCER
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
- (2015) Joel Shapiro et al. LANCET ONCOLOGY
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- Familial Gastric Cancers
- (2015) N. Setia et al. ONCOLOGIST
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Correction: An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers
- (2014) Ajay Goel et al. PLoS One
- Differential clinicopathologic features in microsatellite-unstable gastric cancers with and without MLH1 methylation
- (2012) Kyung-Ju Kim et al. HUMAN PATHOLOGY
- Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas
- (2012) William K. Funkhouser et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- HER2 testing in gastric cancer: a practical approach
- (2012) Josef Rüschoff et al. MODERN PATHOLOGY
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
- (2012) P. van Hagen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gastric cancer in individuals with Li-Fraumeni syndrome
- (2011) Serena Masciari et al. GENETICS IN MEDICINE
- Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
- (2011) Marc Ychou et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma
- (2010) Fei Bao et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
- (2010) Ilfet Songun et al. LANCET ONCOLOGY
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- MUTYH-associated polyposis
- (2009) Julian R. Sampson et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
- (2009) J D Barros-Silva et al. BRITISH JOURNAL OF CANCER
- Germline CDH1 deletions in hereditary diffuse gastric cancer families
- (2009) C. Oliveira et al. HUMAN MOLECULAR GENETICS
- Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
- (2009) William H. Allum et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
- (2009) Michael Stahl et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search